![Page 1: TAT 2011 presentation: Definition of dose-limiting ... · PDF fileDefinition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents Department Hospital](https://reader031.vdocuments.mx/reader031/viewer/2022022503/5aaf99e77f8b9a07498d8e53/html5/thumbnails/1.jpg)
Definition of dose-limiting toxicity in phase I cancer clinical trials of
molecularly targeted agentsDepartment Hospital Town Country
Christophe Le Tourneau Medical Oncology Institut Curie Paris France
Albiruni A.R. Razak Medical Oncology Princess Margaret Hospital Toronto Canada
Hui K. Gan Medical Oncology Austin Hospital Melbourne Australia
Simona Pop Medical Oncology Institut Curie Paris France
Véronique Diéras Medical Oncology Institut Curie Paris France
Patricia Tresca Medical Oncology Institut Curie Paris France
Xavier Paoletti Biostatistics Institut Curie Paris France
March 7th, 2011 – TAT meeting – Paris
![Page 2: TAT 2011 presentation: Definition of dose-limiting ... · PDF fileDefinition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents Department Hospital](https://reader031.vdocuments.mx/reader031/viewer/2022022503/5aaf99e77f8b9a07498d8e53/html5/thumbnails/2.jpg)
Conflicts of interest
• None to disclose
![Page 3: TAT 2011 presentation: Definition of dose-limiting ... · PDF fileDefinition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents Department Hospital](https://reader031.vdocuments.mx/reader031/viewer/2022022503/5aaf99e77f8b9a07498d8e53/html5/thumbnails/3.jpg)
Introduction
• Assessment of dose-limiting toxicity (DLT)
and establishment of the maximum tolerated
dose (MTD) constitute the primary endpoint
of phase I cancer trials
• Guidelines for the use and reporting of
endpoints in phase II/III randomized trials
(CONSORT)
• No consensus on the definition of DLT in
phase I trialsBegg. JAMA 1996;276:637-9
![Page 4: TAT 2011 presentation: Definition of dose-limiting ... · PDF fileDefinition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents Department Hospital](https://reader031.vdocuments.mx/reader031/viewer/2022022503/5aaf99e77f8b9a07498d8e53/html5/thumbnails/4.jpg)
Introduction
• Necessity for standardization of the
definition of DLT in phase I trials?
• Question raised during the 9th NCI/EORTC
New Drug Development Symposium in
Amsterdam in 1996
• Recommendation was to try standardizing
the definition of DLT
• Time of cytotoxic agents
Arbuck. Ann Oncol 1996;7:567-73
![Page 5: TAT 2011 presentation: Definition of dose-limiting ... · PDF fileDefinition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents Department Hospital](https://reader031.vdocuments.mx/reader031/viewer/2022022503/5aaf99e77f8b9a07498d8e53/html5/thumbnails/5.jpg)
Introduction
• Molecularly targeted agents (MTA) display
different toxicity profiles
• Efficacy of these agents may not increase
with dose
• The recommended phase II dose is still
largely based on the determination of the
MTD and therefore on the assessment of DLT
Postel-Vinay. BJC 2009;100:1373-8
![Page 6: TAT 2011 presentation: Definition of dose-limiting ... · PDF fileDefinition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents Department Hospital](https://reader031.vdocuments.mx/reader031/viewer/2022022503/5aaf99e77f8b9a07498d8e53/html5/thumbnails/6.jpg)
Objective
To evaluate how DLT are defined in phase I
cancer clinical trials of MTA administered as
single agents published over the last decade
![Page 7: TAT 2011 presentation: Definition of dose-limiting ... · PDF fileDefinition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents Department Hospital](https://reader031.vdocuments.mx/reader031/viewer/2022022503/5aaf99e77f8b9a07498d8e53/html5/thumbnails/7.jpg)
Methods
Selection of trials:
- MTA
- immunotherapeutics and hormone
therapies were excluded
- PO or IV administration
![Page 8: TAT 2011 presentation: Definition of dose-limiting ... · PDF fileDefinition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents Department Hospital](https://reader031.vdocuments.mx/reader031/viewer/2022022503/5aaf99e77f8b9a07498d8e53/html5/thumbnails/8.jpg)
General results
SCOPUS search from January 1st, 2000
to April 18th, 2010
2,151 references identified
155 phase I cancer
clinical trials
131 phase I cancer
clinical trials of
molecularly targeted agents
Study of the
131 references
Identification of
24 additional
references
![Page 9: TAT 2011 presentation: Definition of dose-limiting ... · PDF fileDefinition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents Department Hospital](https://reader031.vdocuments.mx/reader031/viewer/2022022503/5aaf99e77f8b9a07498d8e53/html5/thumbnails/9.jpg)
Items used to define DLTs
Definition
of
DLT
Items
![Page 10: TAT 2011 presentation: Definition of dose-limiting ... · PDF fileDefinition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents Department Hospital](https://reader031.vdocuments.mx/reader031/viewer/2022022503/5aaf99e77f8b9a07498d8e53/html5/thumbnails/10.jpg)
Items used to define DLTs
0
20
40
60
80
100
120
140
160
![Page 11: TAT 2011 presentation: Definition of dose-limiting ... · PDF fileDefinition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents Department Hospital](https://reader031.vdocuments.mx/reader031/viewer/2022022503/5aaf99e77f8b9a07498d8e53/html5/thumbnails/11.jpg)
Items used to define DLTs
0
20
40
60
80
100
120
140
160HEMATOLOGIC
9 categories
![Page 12: TAT 2011 presentation: Definition of dose-limiting ... · PDF fileDefinition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents Department Hospital](https://reader031.vdocuments.mx/reader031/viewer/2022022503/5aaf99e77f8b9a07498d8e53/html5/thumbnails/12.jpg)
Items used to define DLTs
0
20
40
60
80
100
120
140
160NON-HEMATOLOGIC
47 categories
![Page 13: TAT 2011 presentation: Definition of dose-limiting ... · PDF fileDefinition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents Department Hospital](https://reader031.vdocuments.mx/reader031/viewer/2022022503/5aaf99e77f8b9a07498d8e53/html5/thumbnails/13.jpg)
Items used to define DLTs
0
20
40
60
80
100
120
140
160
ORGAN-SPECIFIC ITEMS
46 categories
![Page 14: TAT 2011 presentation: Definition of dose-limiting ... · PDF fileDefinition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents Department Hospital](https://reader031.vdocuments.mx/reader031/viewer/2022022503/5aaf99e77f8b9a07498d8e53/html5/thumbnails/14.jpg)
Severity of toxicity
Definition
of
DLT
Items
Severity
![Page 15: TAT 2011 presentation: Definition of dose-limiting ... · PDF fileDefinition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents Department Hospital](https://reader031.vdocuments.mx/reader031/viewer/2022022503/5aaf99e77f8b9a07498d8e53/html5/thumbnails/15.jpg)
Severity of toxicity
NCI CTCAE >G2
NCI CTCAE >G3
NCI CTCAE >G4
Not a DLT
Other classification/threshold
Not specified
![Page 16: TAT 2011 presentation: Definition of dose-limiting ... · PDF fileDefinition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents Department Hospital](https://reader031.vdocuments.mx/reader031/viewer/2022022503/5aaf99e77f8b9a07498d8e53/html5/thumbnails/16.jpg)
Severity of toxicity
• Non-hematologic items>G2
>G3
>G4
Not a DLT
Other
Not specified
Non-hematologic, nos Organ-specific items (all)
0
20
40
60
80
100
120
140
160
0
50
100
150
200
![Page 17: TAT 2011 presentation: Definition of dose-limiting ... · PDF fileDefinition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents Department Hospital](https://reader031.vdocuments.mx/reader031/viewer/2022022503/5aaf99e77f8b9a07498d8e53/html5/thumbnails/17.jpg)
Severity of toxicity
• Organ-specific items>G2
>G3
>G4
Not a DLT
Other
Not specified
Vomiting
0
10
20
30
40
50
60
0
1
2
3
4
5
6
7
QTc prolongation
Hypersensitivity reaction
0
1
2
3
4
5
Neurotoxicity
0
1
2
3
4
5
6
7
8
![Page 18: TAT 2011 presentation: Definition of dose-limiting ... · PDF fileDefinition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents Department Hospital](https://reader031.vdocuments.mx/reader031/viewer/2022022503/5aaf99e77f8b9a07498d8e53/html5/thumbnails/18.jpg)
Duration of toxicity
Definition
of
DLT
Items
Severity
Duration
![Page 19: TAT 2011 presentation: Definition of dose-limiting ... · PDF fileDefinition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents Department Hospital](https://reader031.vdocuments.mx/reader031/viewer/2022022503/5aaf99e77f8b9a07498d8e53/html5/thumbnails/19.jpg)
Duration of toxicity
Definition
of
DLT
Items
Severity
Duration
13%
![Page 20: TAT 2011 presentation: Definition of dose-limiting ... · PDF fileDefinition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents Department Hospital](https://reader031.vdocuments.mx/reader031/viewer/2022022503/5aaf99e77f8b9a07498d8e53/html5/thumbnails/20.jpg)
Reversibility of toxicity
Definition
of
DLT
Items
Severity
Duration
Reversi
bility
![Page 21: TAT 2011 presentation: Definition of dose-limiting ... · PDF fileDefinition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents Department Hospital](https://reader031.vdocuments.mx/reader031/viewer/2022022503/5aaf99e77f8b9a07498d8e53/html5/thumbnails/21.jpg)
Reversibility of toxicity
Definition
of
DLT
Items
Severity
Duration
Reversi
bility
12%
![Page 22: TAT 2011 presentation: Definition of dose-limiting ... · PDF fileDefinition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents Department Hospital](https://reader031.vdocuments.mx/reader031/viewer/2022022503/5aaf99e77f8b9a07498d8e53/html5/thumbnails/22.jpg)
Treatment delay
Definition
of
DLT
Items
Severity
Duration
Reversi
bility
Treatment
delay
![Page 23: TAT 2011 presentation: Definition of dose-limiting ... · PDF fileDefinition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents Department Hospital](https://reader031.vdocuments.mx/reader031/viewer/2022022503/5aaf99e77f8b9a07498d8e53/html5/thumbnails/23.jpg)
Treatment delay
Definition
of
DLT
Items
Severity
Duration
Reversi
bility
Treatment
delay
19%
![Page 24: TAT 2011 presentation: Definition of dose-limiting ... · PDF fileDefinition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents Department Hospital](https://reader031.vdocuments.mx/reader031/viewer/2022022503/5aaf99e77f8b9a07498d8e53/html5/thumbnails/24.jpg)
Dose-intensity reduction
Definition
of
DLT
Items
Severity
Duration
Reversi
bility
Treatment
delay
Dose-
intensity
reduction
![Page 25: TAT 2011 presentation: Definition of dose-limiting ... · PDF fileDefinition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents Department Hospital](https://reader031.vdocuments.mx/reader031/viewer/2022022503/5aaf99e77f8b9a07498d8e53/html5/thumbnails/25.jpg)
Dose-intensity reduction
Definition
of
DLT
Items
Severity
Duration
Reversi
bility
Treatment
delay
Dose-
intensity
reduction
8%
![Page 26: TAT 2011 presentation: Definition of dose-limiting ... · PDF fileDefinition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents Department Hospital](https://reader031.vdocuments.mx/reader031/viewer/2022022503/5aaf99e77f8b9a07498d8e53/html5/thumbnails/26.jpg)
Influencing factors
Definition
of
DLT
Items
Severity
Duration
Reversi
bility
Treatment
delay
Dose-
intensity
reduction
Route
Schedule
Recovery time
Dose
escalation
First-in-human
Class of agent
![Page 27: TAT 2011 presentation: Definition of dose-limiting ... · PDF fileDefinition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents Department Hospital](https://reader031.vdocuments.mx/reader031/viewer/2022022503/5aaf99e77f8b9a07498d8e53/html5/thumbnails/27.jpg)
Influencing factors
Definition
of
DLT
Items
Severity
Duration
Reversi
bility
Treatment
delay
Dose-
intensity
reduction
Schedule
Recovery time
![Page 28: TAT 2011 presentation: Definition of dose-limiting ... · PDF fileDefinition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents Department Hospital](https://reader031.vdocuments.mx/reader031/viewer/2022022503/5aaf99e77f8b9a07498d8e53/html5/thumbnails/28.jpg)
Final definition of DLTs
Initial definition
of DLT
Occurrence
of DLT
Final definition
of DLT
RESULTSMETHODS
![Page 29: TAT 2011 presentation: Definition of dose-limiting ... · PDF fileDefinition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents Department Hospital](https://reader031.vdocuments.mx/reader031/viewer/2022022503/5aaf99e77f8b9a07498d8e53/html5/thumbnails/29.jpg)
Final definition of DLTs
Proportion of discrepancies between the
initial and the final definition of DLT
=
25%
![Page 30: TAT 2011 presentation: Definition of dose-limiting ... · PDF fileDefinition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents Department Hospital](https://reader031.vdocuments.mx/reader031/viewer/2022022503/5aaf99e77f8b9a07498d8e53/html5/thumbnails/30.jpg)
Summary
• Heterogeneity of the definition of DLT
• Definition of DLT depends on drug
schedule
• High rate of discrepancies between the
initial and the final definition of DLT
![Page 31: TAT 2011 presentation: Definition of dose-limiting ... · PDF fileDefinition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents Department Hospital](https://reader031.vdocuments.mx/reader031/viewer/2022022503/5aaf99e77f8b9a07498d8e53/html5/thumbnails/31.jpg)
Recommendations
Definition
of
DLT
DLT
assessment
period
Severity- absolute
- relative to
baseline
Duration-where
relevant
-grade-
specific?
Treatment
delay
Dose-
intensity
reduction
Reversibility-where
relevant
-grade-
specific?